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A high incidence of de novo chromosomal aberrations in a population of persons with autism suggests a causal relationship
between certain chromosomal aberrations and the occurrence of autism. A previous study on a Tunisian boy carrying a t(7;16)
translocation identiﬁed the 7p22.1 as a positional candidate region for autism on chromosome 7. The characterization of the
chromosomal breakpoints helped us to identify new candidate regions on chromosome 16p11.2 which contain no known genes
and the other one on 7p22.1 containing a portion of genes (NP 976327.1, RBAK, Q6NUR6 also called RNF216L and MMD2).
We proposed Q6NUR6 (RNF216L) as a candidate gene for autism due to its vicinity to the translocation breakpoint on the
chromosome derivative 7. Q6NUR6 is predicted to be an E3ubiquitin-ligase. Quantitative PCR demonstrates that Q6NUR6 gene
has an ubiquitous expression and that it is strongly expressed in fetal and adult brain. The Q6NUR6 expression is increased in
the patient blood cells in comparison to controls. This is the ﬁrst report of Q6NUR6 gene (E3 ubiquitin ligase TRIAD3 EC 6.3.2)
increasing blood levels in a patient with autism. It’s probably caused by a position eﬀect involving this gene and modifying its
expression.
A wide range of numerical and structural chromosome
abnormalities including translocations, deletions, and dupli-
cations, visible in banding cytogenetic techniques, has been
reported in autistic patients [1]. The high incidence of de
novo chromosomal aberrations in a population of persons
with autism suggests a causal relationship between certain
chromosomal aberrations and the occurrence of autism [2].
We have studied a boy patient with autism and no
dysmorphic features. Cytogenetic and molecular investiga-
tions revealed a de novo balanced translocation 46, XY,
t(7;16)(p22.1;p11.2) in the patient. The karyotypes of the
parents are normal. We mapped the breakpoints of the
translocation on chromosomes 7 and 16 by ﬂuorescence in
situ hybridization (FISH). The characterization of the chro-
mosomal breakpoints helped us to identify new candidate
regions on chromosome 16p11.2 which contains no known
genes and the other one on 7p22.1 containing a portion of
genes (NP 976327.1, RBAK, Q6NUR6 also called RNF216L
and MMD2) [3].
Metaphase spreads from the patient, her parents, and
controls were obtained using standard protocols either
from short-term blood lymphocyte cultures or from EBV-
transformed lymphoblastoid cell cultures. Whole chromo-
some paints screen conﬁrmed the presence of the t(7;16)
translocation, showed that the chromosomal rearrangement
implicates the chromosomes 7 and 16 only, and established
that the translocation is reciprocal and apparently balanced
(Figure 1(a)).
In order to ﬁnemap the breakpoint on 7p22.1, we
performed FISH using BAC End clones from this chro-
mosomal region as probes. BAC DNAs (RPCI-11 library)
were biotinylated with biotin-11-dUTP (Sigma) by nick
translation using the Bio Nick Labelling System (Invitrogen
Life Technologies) according to the instructions of the
manufacturers. Hybridization was performed using the
standard procedures. After several rounds of hybridization,
we identiﬁed one genomic BAC End clone (RP11-152I5)2 Journal of Biomedicine and Biotechnology
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Figure 1: Physical mapping of the breakpoint on chromosome 7. (a) Dual color painting using directly FITC labelled (green) chromosome 7
paint and Rhodamine labelled (red) chromosome 16 paint. Both derivatives 7 and 16 (arrow) show clear evidence of a reciprocal exchange of
chromatin from distal 7p and distal 16p, respectively. (b) Physical map of the genomic region 7p22.1 derived from the October 2009 version
of the UCSC Genome Browser (http://genome.ucsc.edu/). The genomic clones covering the region ﬂanking the translocation breakpoint are
indicated by black lines (S: spanning, NT: non-translocated). The breakpoint (Bp) region is represented by an arrow. The genomic location
of candidate genes is represented by rectangles.
speciﬁcofband7p22.1andwhichisspanningthebreakpoint
on chromosome 7.
We analyzed 50 metaphases and noticed that the signal
on chromosome derivative 16 was repeatedly larger than
the signal of chromosome derivative 7. These results suggest
that the breakpoint on chromosome 7 is in the region
corresponding to the centromeric half of BAC RP11-152I5
(Figure 1(b)).
Based on our results and according to the UCSC genome
database (http://genome.ucsc.edu), we proposed Q6NUR6
(RNF216L) as a candidate gene for autism due to its
vicinity to the translocation breakpoint on the chromosome
derivative 7. The Q6NUR6 gene (GeneID: 441191) maps to
chromosome 7p22.1 and contains 8 exons (only exons 4,
5 and 6 are coding), encompassing 24,183Kb of genomic
DNA. The gene transcribes an mRNA (BC068459) ofJournal of Biomedicine and Biotechnology 3
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Figure 2: Quantitative expression of Q6NUR6 gene. (a) The expression pattern of the Q6NUR6 gene in various human tissues, fB: fœtal
brain; Br: brain; Bl: blood; Li: liver; T: testis; Lu: lung. (b, c) Quantitative Expression of Q6NUR6 gene in the patient and controls. QRT-
PCR was done on RNA extracted from blood cell lines. A signiﬁcantly higher expression level was detected in the patient compared with
normalcontrolindividuals (b)andwithautisticpatientswithoutchromosomalanomalies (c).Theexpressionnormalizationwasdoneusing
the ribosomal 18S gene. (AR: Patient; NTC: No Template Control; T2, T3, T4, T6, T7: Healthy control individuals; P1, P2, P3, P4: autistic
patients without chromosomal anomalies).
2,427Kb that encodes a 75-amino-acid protein. The protein
shows great homology with TRIAD3 gene. Its function is
currently unknown but Q6NUR6 is predicted to be an E3
ubiquitin-ligase.
Approximately 23kb of Q6NUR6 (including the pro-
moter region) are located in the region corresponding
to BAC RP11-152I5 (spanning the 7p22.1 breakpoint)
(Figure 1(b)). To test whether this part of the gene was
interrupted by the translocation breakpoint we performed
Southern blot experiments to explore the genomic region
containing the Q6NUR6 gene and its promoter on the
patient’s and a control DNA. All Southern blots gave normal
results with restriction fragments at the expected sizes
(data not shown), indicating that the Q6NUR6 gene or its
promoter is not interrupted by the translocation breakpoint
on chromosome 7.
Because Q6NUR6 gene is close to, but not interrupted
by, the 7p22.1 breakpoint, we wanted to determine if its
expression is altered by the presence of the translocation
breakpoint.
Total RNA was isolated and puriﬁed using the RNAgents
Total RNA Isolation System (Promega) from peripheral
white blood cells and EBV cell lines of the patient and
controls. DNAse treatment was performed for 30minutes
with 1mg of RNA, 1U of RNAse-free DNAse I (Qiagen
GmbH, Germany). Total RNA was used in conjunction
with AMV reverse transcriptase and random hexamers
(Promega) to generate ﬁrst strand cDNA. For the PCR step,
1μg of total RNA converted to cDNA was used in 25μL
reactions with TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). For the Q6NUR6 gene
the corresponding sequence-speciﬁc primers/probes assay
mix (Hs00415445 m1) was used. Fluorescence detection was
measured utilizing an ABI Prism 7500 platform (Applied
Biosystems). After an initial step at 50◦Cf o r2 m i n u t e s ,
t h e r ew a sa na c t i v a t i o ns t e pa t9 5 ◦C for 10minutes. Thermal
cycling proceeded with 50 cycles at 95◦C for 15seconds and
1minute at 60 ◦C. Normalization to the ribosomal18s and
to the beta-2-microglobulin (B2M) control genes was per-
formed to account for variability in the initial concentration
and quality of total RNA and in the conversion eﬃciency of
the reverse transcription reaction.
All PCR reactions were performed in triplicate and
changes in gene expression between the control (or cali-
brator) and treated samples after normalisation to the gene
reference was calculated using the comparative threshold
cycle (CT) method where relative amount is equal to 2−ΔΔCT,4 Journal of Biomedicine and Biotechnology
and where ΔΔCT is the ΔCT of the target gene (threshold
cycle test gene—threshold cycle endogenous control) minus
the ΔCT of the calibrator sample (threshold cycle calibrator
gene—threshold cycle endogenous control).
Quantitative PCR demonstrates that Q6NUR6 gene has
an ubiquitous expression and that it is strongly expressed in
foetal and adult brain (Figure 2(a)). The Q6NUR6 expres-
sion is increased in the patient blood cells in comparison
to controls (the control RNA originates from individuals
without disease phenotype or chromosomal aberration).
As shown in Figure 2(b), Q6NUR6 is overexpressed in the
patientratherthaninhealthycontrolbloodcells.Therelative
quantiﬁcation of Q6NUR6 gene expression was established
to 29.33.
The average of the expression on normal control individ-
ualswascalculatedas0.9687excludingapossibleduplication
ofthisgene.Thethresholdforoverexpressionwasestablished
asabout30-foldthevalueforthenormalcontrolsinEBV-cell
lines.
To determine if this increase is caused by the translo-
cation, we quantiﬁed the expression of Q6NUR6 in the
patient’s cell line and in four autistic patients without
chromosomal aberrations (Figure 2(c)). The overexpression
is the same that seen previously. This result means that the
variation of Q6NUR6 gene expression seen in the patient cell
line is probably caused by the translocation.
Quantitative RT-PCR was also used to verify if the
remaining chromosome 7 candidate genes were diﬀerentially
expressed in the patient and the control cases. NP 976327.1
gene was not expressed in blood and ﬁbroblasts. RBAK and
MMD2 genes were expressed at the same level in patient and
controls (data available upon request).
The Q6NUR6 gene has been localized to 7p22.1 by
the Mammalian Gene Collection [4]. This gene has been
described as a pseudogene in Gene at NCBI database
(www.ncbi.nlm.nih.gov/). However, it has been consid-
ered to be a protein coding gene by Ensembl Genome
Browser (http://www.ensembl.org/). The Bgee database
(http://bgee.unil.ch/) demonstrates that Q6NUR6 gene is
expressed in a variety oh human tissues (like brain and
hippocampus) at all developmental stages.
Our data demonstrate the ubiquitous expression of this
gene and its overexpression in an autistic patient carrying a
t(7;16)(22.1;p11.2) reciprocal translocation.
Chromosomal aberrations, when they do not interrupt a
gene, sometime lead to the modiﬁcation of the expression of
a gene due to the alteration of its environment, the so-called
“position eﬀect.” The rearrangement may juxtapose the gene
with an enhancer element from another gene leading to
inappropriate gene expression [5]. This is the ﬁrst report
of Q6NUR6 gene (E3 ubiquitin ligase TRIAD3 EC 6.3.2)
increasing blood levels in a patient with autism probably
caused by a position eﬀect involving this gene and modifying
its expression.
Q6NUR6 is predicted as an E3 ubiquitin ligase from
protein sequence homology with the TRIAD3 protein.
Abnormalities in other E3 ubiquitin ligases have been
described earlier in number of psychiatric diseases [6].
Mutations in E3 ligases were identiﬁed as causative for
Angelman syndrome [MIM:105830] (UBE3A gene) and
recessive juvenile Parkinson disease [MIM:600116] (PARK2
gene) [7].
In conclusion, all the data collected during the course of
this study suggest that the Q6NUR6 gene may be implicated
in the autistic phenotype of the reported patient, and that
this phenotype is possibly caused by the presence of the
translocation. The exact functions of Q6NUR6 gene in
mammalian cells are still unclear and ﬁnal genetic evidence
linking this gene to autism will be obtained by the detection
of mutations in this gene in other patients with autism, or
theassociationofpolymorphismsinthiscandidategenewith
autism.
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